Home › Research › Tau biomarkers
From clinical judgment to biology: a clinician's opinion on the use of blood-based biomarkers in Alzheimer's disease
Raúl Medina-Rioja, Aranza Llorente-Vidrio, Ramiro Ruiz‐Garcia, Mayela Rodríguez‐Violante. Frontiers in Neurology, 2026-04-08
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This position is justified by the fact that not all individuals with positive biomarkers will progress to symptomatic disease, as well as by the considerable variability in biomarker results depending on the type of marker and the laboratory performing the analysis (3).Both frameworks agree that biomarkers enhance diagnostic certainty but differ in the degree of reliance placed upon them. Autopsy studies have revealed significant clinicopathological discordance, reflecting the heterogeneity of dementia and frequent mixed pathologies. While biomarkers improve diagnostic precision, these findings highlight that uncertainty persists and reinforce the need for their interpretation within a clinical framework (4).Currently available biomarkers include CSF measurements (Aβ42/Aβ40 ratio, total tau, and phosphorylated tau), PET imaging (amyloid), and more recently blood-based biomarkers (Aβ42/Aβ40 ratio, p-tau217, and p-tau181) (5).Among these, p-tau217 stands out for its superior diagnostic accuracy compared with other epitopes such as p-tau181, achieving sensitivities and specificities close to 85-90% for identifying amyloid and tau positivity, particularly when combined with Aβ42. Additionally, they have shown the ability to distinguish Alzheimer's disease from other dementias (1).One of the main risks associated with blood-based biomarkers is that they may be elevated in other conditions. Ordering biomarkers without a clear indication or overinterpreting their results may lead to false diagnoses of AD in healthy individuals or in those with a different primary etiology, with potentially significant consequences, particularly in the current era, where biological therapies are becoming increasingly relevant.Blood-based biomarkers represent a major advance in the diagnosis of Alzheimer's disease by providing accessible and accurate detection of underlying pathology.
What this study adds
Evidence grade: Low
This clinician's opinion piece states that blood-based biomarkers such as p-tau217 and the Aβ42/Aβ40 ratio can improve diagnostic certainty, with p-tau217 reaching sensitivities and specificities near 85-90% for identifying amyloid and tau positivity. It cautions that not everyone with positive biomarkers will develop symptoms, results vary by marker and laboratory, and autopsy studies show significant clinicopathological discordance, so biomarkers must be interpreted within a clinical framework.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Medina-Rioja, R., Llorente-Vidrio, A., Ruiz‐Garcia, R., & Rodríguez‐Violante, M. (2026). From clinical judgment to biology: a clinician's opinion on the use of blood-based biomarkers in Alzheimer's disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2026.1804163
Vancouver
Medina-Rioja R, Llorente-Vidrio A, Ruiz‐Garcia R, Rodríguez‐Violante M. From clinical judgment to biology: a clinician's opinion on the use of blood-based biomarkers in Alzheimer's disease. Frontiers in Neurology. 2026. doi:10.3389/fneur.2026.1804163. PMID: 42028213.
BibTeX
@article{medinarioja2026-42028213,
author = {Medina-Rioja, Raúl and Llorente-Vidrio, Aranza and Ruiz‐Garcia, Ramiro and Rodríguez‐Violante, Mayela},
title = {{From clinical judgment to biology: a clinician's opinion on the use of blood-based biomarkers in Alzheimer's disease}},
journal = {Frontiers in Neurology},
year = {2026},
doi = {10.3389/fneur.2026.1804163},
pmid = {42028213},
url = {https://doi.org/10.3389/fneur.2026.1804163}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This position is justified by the fact that not all individuals with positive biomarkers will progress to symptomatic disease, as well as by the considerable variability in biomarker results depending on the type of marker and the laboratory performing the analysis (3).Both frameworks agree that biomarkers enhance diagnostic certainty but differ in the degree of reliance placed upon them.
- Autopsy studies have revealed significant clinicopathological discordance, reflecting the heterogeneity of dementia and frequent mixed pathologies.
- While biomarkers improve diagnostic precision, these findings highlight that uncertainty persists and reinforce the need for their interpretation within a clinical framework (4).Currently available biomarkers include CSF measurements (Aβ42/Aβ40 ratio, total tau, and phosphorylated tau), PET imaging (amyloid), and more recently blood-based biomarkers (Aβ42/Aβ40 ratio, p-tau217, and p-tau181) (5).Among these, p-tau217 stands out for its superior diagnostic accuracy compared with other epitopes such as p-tau181, achieving sensitivities and specificities close to 85-90% for identifying amyloid and tau positivity, particularly when combined with Aβ42.
- Additionally, they have shown the ability to distinguish Alzheimer's disease from other dementias (1).One of the main risks associated with blood-based biomarkers is that they may be elevated in other conditions.
- Ordering biomarkers without a clear indication or overinterpreting their results may lead to false diagnoses of AD in healthy individuals or in those with a different primary etiology, with potentially significant consequences, particularly in the current era, where biological therapies are becoming increasingly relevant.Blood-based biomarkers represent a major advance in the diagnosis of Alzheimer's disease by providing accessible and accurate detection of underlying pathology.
Why it matters
This clinician's opinion piece states that blood-based biomarkers such as p-tau217 and the Aβ42/Aβ40 ratio can improve diagnostic certainty, with p-tau217 reaching sensitivities and specificities near 85-90% for identifying amyloid and tau positivity. It cautions that not everyone with positive biomarkers will develop symptoms, results vary by marker and laboratory, and autopsy studies show significant clinicopathological discordance, so biomarkers must be interpreted within a clinical framework.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Neurology) |
| Journal's citation record | 2 / 4 | Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mayela Rodríguez‐Violante: h-index 34 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Instituto Nacional de Neurología y Neurocirugía: institution h-index 199 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42028213) |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fneur.2026.1804163
- PubMed: 42028213
- Original source →
- Free full text: Frontiers in Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.